Concordia Completes Acquisition of Cinven-backed AMCo
October 23, 2015
Concordia Healthcare (NASDAQ: CXRX) has completed its acquisition of Amdipharm Mercury (AMCo) from Cinven in a transaction valued up to approximately $3.5 billion; Cinven will hold roughly 14.2% of Concordia’s outstanding common shares on a non-diluted basis. The combined company is expected to achieve revenue and adjusted EBITDA of over $870 million and $510 million, respectively. AMCo is an international pharmaceutical company formed from the 2013 merger of Amdipharm and Mercury Pharma, both acquired by Cinven in 2012.